Nasal dosage forms formulation development

A third area to consider is the generation of an enhanced product that adds value to the original finished dosage form. Product enhancements include, for example, other forms of dehvery (e.g., transder-mal, nasal, inhalable, etc.) or new formulations. Examples among the biopharmaceuticals are the development of inhaled insulins, e.g., Exubera currently in phase III clinical trials developed by Nektar Therapeutics, Pfizer, and Aventis (admittedly, this work is not driven by a potential generic threat, but primarily by the enormous market potential of an insuhn that does not have to be injected) (see also Part VI, Chapter 2). 

---